UK and certain European countries lose WHO’s measles-free status
The UK is one of several European countries to lose its status as measles-free amid a diminishing uptake of the…
27 Jan 2026
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline
Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver diseases. Agreed in December 2025, the transaction is valued at up to $820m…
27 Jan 2026
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental biologics licence application (sBLA) submitted by the former for Leqembi Iqlik…
26 Jan 2026
Internet of Medical Things beats AI as top ranked growth driver among life science CEOs
A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the most important capability towards driving growth, accelerating R&D, and unlocking…
26 Jan 2026
UK biotechs suffered restricted financing in 2025
Both the amount of equity financing and venture capital attracted by UK biotechs dropped in 2025, compounding concerns for the level of the country’s life science industry attractiveness on the…
26 Jan 2026
MSD ends takeover talks with Revolution Medicines
Merck & Co (MSD) is no longer in talks to acquire oncology biotech Revolution Medicines after negotiations hit a stumbling block over valuations, according to the Wall Street Journal (WSJ).…
26 Jan 2026
NICE greenlights Pfizer’s Talzenna for NHS use
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Talzenna (talazoparib) in a step forward for patients in England with prostate cancer. Following the NICE’s decision…